The number of reported global daily deaths from the coronavirus reached 10,816 on Nov. 17, according to a Reuters tally, the highest single-day death count as the virus’ global epicenter the United States entered winter.
Johnson & Johnson launched a new late-stage trial in Britain to test a two-dose regimen of the company’s experimental Covid-19 vaccine among thousands of volunteers, as the U.S. drugmaker’s clinical studies expand by geography and type.
Global coronavirus infections exceeded 50 million, according to a Reuters tally, with a second wave of the virus in the past 30 days accounting for a quarter of the total.
The painkiller aspirin will be evaluated as a possible treatment for Covid-19 in one of Britain’s biggest trials, which will assess whether it might reduce the risk of blood clots in people with the disease.
Late-stage trial results of a potential Covid-19 vaccine being developed by the University of Oxford and AstraZeneca could be presented in 2020 as the British government prepares for a possible vaccination rollout in late December or early 2021.
(Reuters) – AstraZeneca Plc said on Sunday Britain’s health regulator had started an accelerated review of its potential coronavirus vaccine. “We confirm the MHRA’s (Medicines and Healthcare Products Regulatory Agency) rolling review of our potential COVID-19 vaccine,” an AstraZeneca spokesman said. In rolling reviews, regulators are able to see clinical data in real time and […]
Antibodies against the novel coronavirus declined rapidly in the British population during the summer, a study found, suggesting protection after infection may not be long lasting and raising the prospect of waning immunity in the community.
The widely used BCG tuberculosis vaccine will be tested on frontline care workers in Britain for its effectiveness against Covid-19, researchers running the UK arm of a global trial said.
The global coronavirus death toll surpassed 1 million according to a Reuters tally, a bleak statistic in a pandemic that has devastated the global economy, overloaded health systems and turned daily life upside down.
The adverse events that led to a pause in trials evaluating AstraZeneca Plc’s Covid-19 vaccine candidate may not have been associated with the vaccine itself, according to a document outlining participant information that was posted online by the Oxford University.